Mundipharma, a global network of privately-owned independent associated companies, has acquired Spanish biosimilars development company Cinfa Biotech from Infarco for an undisclosed price.
Cinfa Biotech, which was founded in 2013, has offices in Munich, Germany and Pamplona, Spain.
The company, which is part of Spanish pharma firm Cinfa Group, is engaged in the development of a pipeline of biosimilar drugs for various indications.
Mundipharma said that the acquisition will give added development capabilities to its biosimilars platform.
The acquisition will also enable the Mundipharma network, which includes the UK-based NAPP Pharmaceuticals, to gain immediate access to Pelmeg (B12019), a biosimilar to Neulasta (pegfilgrastim).
Mundipharma International president and CEO Alberto Martinez said that the network’s biosimilars platform is an important part of its growth strategy and the acquisition is the next step to stay agile and innovative in the biosimilars sector.
Martinez added: “By acquiring Cinfa Biotech we have now taken the first step in our plans to, not only expand our biosimilars footprint, but to develop future biosimilars which will continue to afford healthcare systems further savings and, in some cases, wider access for patients.”
Recently, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Pelmeg, which is a pegylated version of granulocyte-colony stimulating factor (G-CSF).
The Neulasta biosimilar has been developed for the treatment of chemotherapy-induced neutropenia. Pelmeg functions by stimulating the bone marrow to create more neutrophils, thereby decreasing the chances of infection.
Infarco president Enrique Ordieres said: “After having successfully developed and manufactured our first biosimilar, we strongly believe Mundipharma is best placed to take Pelmeg forward through the Cinfa Biotech acquisition.
“They have the pedigree and proven track record of launching biosimilars in Europe, have built strong partnerships with payers, hospital specialists and decision makers and have the deep local understanding of complex tender environments.”
Earlier this year, Mundipharma expanded its partnership with Celltrion Healthcare Hungary by securing exclusive distribution rights across seven EU markets for Herzuma, a biosimilar to trastuzumab biosimilar.